Ovid Therapeutics (OVID) Fundamental Analysis: Revenue, Earnings & Valuation

1.09 / 10

Underperform

Fundamentally OVID is rated Underperform with a low composite score of 1.09. Core metrics such as Accounts Receivable (2) and Fixed Assets turnover (2) are weak, while Revenue‑MV and Asset‑MV provide slight upside. Overall fundamentals remain concerning.

Analysis Checks(5/10)

Revenue-MV

Value-3.47

Score1/3

Weight38.27%

1M Return5.06%

Total operating revenue (YoY growth rate %)

Value1181.27

Score1/3

Weight-8.80%

1M Return-1.40%

Inventory turnover ratio

Value106.57

Score3/3

Weight-4.10%

1M Return-0.67%

Accounts receivable turnover ratio

Value23.61

Score2/3

Weight-4.06%

1M Return-0.65%

PB-ROE

Value-0.30

Score1/3

Weight38.29%

1M Return5.22%

Income tax / Total profit (%)

Value0.00

Score0/3

Weight-9.23%

1M Return-1.54%

Fixed assets turnover ratio

Value0.58

Score2/3

Weight-6.48%

1M Return-1.01%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-4.58%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-4.50%

1M Return-0.74%

Asset-MV

Value-0.55

Score1/3

Weight65.18%

1M Return7.28%

Is OVID undervalued or overvalued?

OVID scores 1.09/10 on fundamentals and holds a Premium valuation at present. Backed by its -17.51% ROE, -240.13% net margin, -18.33 P/E ratio, 2.44 P/B ratio, and 37.84% earnings growth, these metrics solidify its Underperform investment rating.